Mary Beth Scholand

Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial

Donald P. Tashkin, Michael D. Roth, Philip J. Clements et al. · The Lancet Respiratory Medicine · 2016 · 1K citations · Full text

Sls Ii, Mycophenolate Mofetil, Inflammatory Lung Disease +9

Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial

Athol U. Wells, Kevin R. Flaherty, Kevin K. Brown et al. · The Lancet Respiratory Medicine · 2020 · 522 citations · Full text

Inbuild Trial, Parallel-group Trial, Advanced Lung Disease +5

Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: an analysis of the SPIROMICS cohort

Annette T. Hastie, Fernando J. Martínez, Jeffrey L. Curtis et al. · The Lancet Respiratory Medicine · 2017 · 307 citations · Full text

Epidemiology, Blood Eosinophil Concentrations, Advanced Lung Disease +8

Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort

MeiLan K. Han, P. Miguel Quibrera, Elizabeth E. Carretta et al. · The Lancet Respiratory Medicine · 2017 · 304 citations · Full text

Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial

Luca Richeldi, Evans R. Fernández Pérez, Ulrich Costabel et al. · The Lancet Respiratory Medicine · 2019 · 275 citations

Fibrosis, Antifibrotic Therapy, Inflammatory Lung Disease +10